Nasdaq
Nasdaq to Delist Centogene
The German firm did not appeal the decision and will be delisted after having failed to achieve certain milestones to retain its status as a listed company.
OpGen Shares Suspended From Trading on Nasdaq
The suspension comes as the molecular diagnostics firm struggles to meet the Nasdaq's minimum stockholders’ equity requirement.
Centogene Delisted From Nasdaq
The German rare disease company expects its common stock to begin trading on the OTC Markets Group platform on Aug. 8 under the ticker symbol CNTGF.
Bionano Genomics Receives Nasdaq Delisting Warning Over Low Share Price
The San Diego-based optical genome mapping company has 180 calendar days to regain compliance with the minimum bid price requirement.
Oncocyte Notified That It Lost, Regained Nasdaq Compliance
The issue arose with the death in April of a board member, who was also a member of Oncocyte's audit committee, and was resolved with a new appointment this month.